Home' Australian Pharmacist : October 2011 Contents Vol. 30 -- October #10, 2011
growth healthy to 2018
The global allergic conjunctivitis
therapeutics market is forecast to
grow at a compound annual growth
rate (CAGR) of 14.3% until 2018.
A recent GlobalData, report, Allergic
conjunctivitis therapeutics -- pipeline
assessment and market forecasts
to 2018, valued the market at $970
million in 2010 and expects it to reach
$2.8 billion by 2018. According to the
report, increased disease awareness
is anticipated to lead to a growth in
the diagnosed and treated population
which will be further complemented by
rising compliance due to the availability
of a sufficient number of treatment
options including branded, generics
and over-the-counter (OTC) products.
These are expected to be the primary
drivers for the growth of the allergic
conjunctivitis therapeutics market in
the future. No major pipeline products
are expected to drive the market.
GlobalData`s research indicates that
the current treatment options are
focused on offering relief from the
symptoms of allergic conjunctivitis
such as itching, redness and swelling,
which it serves reasonably well.
However, it found low unmet need in
the market relating to relief from the
chronic form of the disease, requiring
the introduction of novel therapies.
Despite this unmet need the pipeline
is weak, with the only major late stage
products being modified pollen extracts
which cater to a niche population.
These, the report said, will not affect
a significant portion of the diseased
population and will not fulfil overall
unmet need relating to the severe form
of the disease in chronic condition.
However, the existing market landscape
remains competitive, because the
treatment of allergic conjunctivitis
relies on established therapies such
as antihistaminic, mast cell stabiliser,
dual-action agents, corticosteroids and
non-steroidal anti-inflammatory drugs
(NSAIDS). The increased prevalence,
diagnosed and treated population of
allergic conjunctivitis is expected to
boost the current market.
The significant increase in the number
of treated patients amongst the
population is the principal driver of
the allergic conjunctivitis therapeutics
market, and this will continue to be so
in the future. In the US, approximately
70 million people are suffering from
allergic conjunctivitis and it is estimated
that there will be a 20% growth in
the number of treated patients each
year. Hence, an increase in the treated
patient population will lead to an
increased use of therapeutic drugs.
HRT market slow to 2018
The global post-menopausal HRT
market was valued at $1.3 billion in
2010, and is forecast to stabilise at a
compound annual growth rate (CAGR)
of 0.7% and reach $1.4 billion by 2018,
according to a new GlobalData report.
The report, Post-Menopausal Hormone
Replacement Therapy (HRT) -- Pipeline
Assessment and Market Forecasts
to 2018 found that the HRT market is
primarily stagnant and dominated by
oral and topical estrogen formulations.
Rising drug prices and an increase in
the elderly population to an extent
have negated the decrease in the
prescription rate of HRT.
The report attributed the decrease
in the prescriptions as a result of
the Women's Health Initiative (WHI)
study, which terminated in 2002, and
showed an increased risk of severe
adverse events including breast
cancer, endometrial cancer and stroke
in women on HRT. The WHI study
affected the entire HRT market during
2002--2005. The report said that doubts
still surround the safety of combination
HRT, although the prescription of oral
and topical estrogens appears to have
stabilised in recent years due to the
lower risk of serious adverse events
associated with such drugs.
Consequently, patients' and physicians'
poor acceptance of HRT is a major
restraint to the market. A shift towards
relatively safer low-dose and ultra-
low-dose post-menopausal HRT such
as Premarin (0.3 mg) and Prempro
(0.3 mg/1.5 mg) contributed to the
stabilisation of the HRT market during
The launch of Pfizer's Aprela, a
combination of conjugated estrogens
(CE) and bazedoxifene (BZA), in 2012
is expected to positively impact
GlobalData's research indicates that
the post-menopausal HRT pipeline is
weak, with few promising hormonal
products under development.
A hormonal drug with improved
safety and efficacy has the potential
to increase the size of the post-
menopausal HRT market.
The 2002 WHI study significantly
and negatively affected the post-
menopausal HRT market and led
to increased concerns among HRT
patients. Despite the 2007 WHI
re-analysis, which suggested that HRT
is not as harmful as originally thought,
concerns among post-menopausal
women regarding the use of HRT still
exist. The decline in the prescription rate
of HRT is yet to completely recover. As
a result, high unmet need exists in the
post-menopausal HRT market in terms
of safety and patient compliance.
Bayer AG and Pfizer are expected to
be the key future market participants,
due to Bayer's launch of Vaginorm,
which is expected to positively affect
the post-menopausal HRT market with
an innovative mechanism of action.
Pfizer's Aprela, which is a combination
of selective estrogen receptor
modulator (SERM) and CE, has shown
a high safety profile and the reduced
risk of severe adverse events.
IBS therapeutics market
A huge unmet need exists for the IBS
therapeutics market a GlobalData,
report, Irritable Bowel Syndrome (IBS)
Therapeutics - Pipeline Assessment and
Market Forecasts to 2018 has found.
It estimates that the global IBS
therapeutics market was valued at
$655.8m in 2010, and is expected
to grow at a compound annual
growth rate (CAGR) of 11.7% in the
forecast period to reach $1.6 billion
by 2018. The high projected growth
rate is primarily attributable to
a strong pipeline and increasing
disease awareness. Increases in the
prevalence of the disease and the
launch of new first-in-class therapies
with better safety and efficacy profiles
are expected to drive the growth of
the IBS therapeutics market.
GlobalData found that currently
competition in the IBS drug area
is weak. Amitiza (lubiprostone)
from Sucampo Pharmaceuticals,
and Lotronex (alosetron) from
GlaxoSmithKline are the two approved
drugs present in the market, for
the treatment of IBS-C and IBS-D
respectively, in the US, while
Irribow (ramosetron) from Astellas
Pharmaceuticals is available in Japan.
Links Archive November 2011 September 2011 Navigation Previous Page Next Page